Interestingly, all transformations to AML in our JAK2-R1063H-positive group occurred in patients initially diagnosed with ET; two of these ET patients carried the CALR driver mutation, none of them carried a mutation in the TP53 gene. This evidence concerns the gene TP53 and essential thrombocythemia.